- Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
- Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
- Aurinia Pharmaceuticals Shareholder Urges Board of Directors to Take Action to Enhance Shareholder Value
- Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
- Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
- Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
- The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
- UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
- Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
- Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference
More ▼
Key statistics
On Friday, Aurinia Pharmaceuticals Inc (AUPH:NMQ) closed at 5.76, 22.29% above the 52 week low of 4.71 set on Apr 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.80 |
---|---|
High | 5.83 |
Low | 5.65 |
Bid | 5.70 |
Offer | 5.84 |
Previous close | 5.77 |
Average volume | 1.44m |
---|---|
Shares outstanding | 143.02m |
Free float | 132.89m |
P/E (TTM) | -- |
Market cap | 823.79m USD |
EPS (TTM) | -0.4363 USD |
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
More ▼